Hold residual BMY for dividend carry and floor optionality pending technical repair triggers
HOLD is intellectually honest because the aggressive analyst's structural floor case (9.61x forward P/E, $8.1B TTM FCF, $6B deleveraging, covered 4% dividend, 0.227 beta, intact 200 SMA, arlo-cel Phase 2 wins) is too compelling to support additional trim or full Sell — the 9/17 trim already captured the calibrated partial adjustment. Simultaneously, the conservative analyst's timing and technical case (50 SMA break on 2-3x volume, MACD expanding negative at -0.54, RSI rolling from >70 to 40.80, Eliquis LoE timing mismatch) is too coordinated to support adding at $63.06 — catching a falling knife with roughly 1:1 asymmetry on the realistic $58-72 range rather than the aggressive's claimed 1:3 risk/reward anchored on an optimistic 12x target. The 9/17 trim already implemented the only calibrated adjustment available. Holding the residual for dividend carry and floor optionality while awaiting one of three defined re-entry triggers is the alpha-generating move.
| Position | Action |
|---|---|
| Panic exhaustion: close below $61.97 with RSI below 30 | Scale to starter add |
| Confirmed reclaim of $64.01 with declining volume and MACD histogram inflecting positive | Full sizing on trend re-entry |
| Sideways consolidation between $62.50-$64.00 for 8-10 trading sessions with declining volume and RSI stabilizing 35-45 | Starter add on range-trading basis with tighter $61.00 stop |
BMY is a self-funding turnaround with record earnings, single-digit forward P/E, a covered 4% dividend, accelerating deleveraging, and fresh pipeline wins that the market hasn't yet repriced, making the current technical weakness a buying opportunity rather than a breakdown.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 64.01 | bearish |
| close_200_sma | 58.09 | bullish |
| close_10_ema | 64.09 | bearish |
| macd | -0.34 | bearish |
| macd_signal | +0.20 | bearish |
| macd_histogram | -0.54 | bearish |
| rsi_14 | 40.80 | bearish |
| bollinger_midband | 65.67 | neutral |
| bollinger_upper | 69.38 | neutral |
| bollinger_lower | 61.97 | bearish |
| vwma_20 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed reclaim of $64.01 on declining volume with MACD histogram inflecting positive
Then: Full sizing on trend repair confirmation
The 50 SMA technical break is explained by ex-dividend date mechanics, not fundamental shareholder exodus
↩ rebuts: “The bear's 50 SMA break argument”
EV: Target $68–70 on pipeline re-rating and dividend yield compression; entry zone toward $61.97 (Bollinger lower band) · concedes: Short-term momentum signals (MACD histogram expanding negative, RSI sliding) are real and observable; Today's volume was heavy on the down day; One program discontinuation (Orum) is acknowledged, though pipeline attrition happens at every pharma company; The patent cliff for Eliquis and Revlimid is real
BMY is a fair-to-good company at an unfair-to-good price — the bear sees a leveraged pharma with a known revenue cliff, deteriorating technicals, and a market correctly pricing risk until proven otherwise.
· concedes: BMY is not a bad company — it's a fair-to-good company at an unfair-to-good price; Eliquis is a first-in-class drug with genuine commercial value before LoE; Debt is being reduced (down $6B in 9 months); Cobenfy represents a novel mechanism (first for schizophrenia in decades) — true; Sotyktu has 2-year PsA durability data
→ vs conservative: 50 SMA break and bearish MACD/RSI are lagging momentum indicators wrong at every major bottom; waiting for MACD inflection and RSI above 50 means missing $66-67 upside by 2-4 sessions
→ vs conservative: Mechanically dismissing 36.8M share volume as ex-dividend selling is intellectually dishonest; even at half, 15-18M shares of genuine distribution was absorbed with price bouncing from $62.84 to $63.60, indicating hold not breakdown
→ vs conservative: Stop-loss trigger at $61.97 is paralysis dressed as discipline; waiting for close below lower Bollinger with RSI below 30 means likely testing 200 SMA at $58.09 where trend appears broken and trader is too terrified to add
→ vs neutral: Eliquis patent cliff already priced in at 9.61x multiple; neutral analyst incorrectly claims 'catalysts are priced in' when arlo-cel is still Phase 2 with re-rating not yet occurred
→ vs neutral: 'Accumulate on weakness' defined as breakdown below $61.97 is trying to catch falling knife after missing first bounce; best entries come when crowd is uncertain and technicals look ugly, not after confirmation
→ vs neutral: 1:1 risk/reward framing is lazy; asymmetric tailwinds from value floor, dividend yield, beta profile, and pipeline optionality make current entry compelling at 9.61x forward P/E
| 64.52 |
| bearish |
| atr_14 | 1.40 | neutral |
| volume | 36,831,221 | bearish |
| close | 63.06 | neutral |
| days_range | 62.19-63.06 | neutral |
Support: 62.19 · 61.97 · 58.09 · 55 | Resistance: 64.01 · 65.67 · 67.66 · 68.09
BMY's technical profile shows a conflict between intact long-term bullish structure (price 8.6% above 200 SMA at $58.09) and deteriorating short-term momentum (broken below 50 SMA and 10 EMA, RSI sliding to 40.80, MACD bearish crossover with expanding negative histogram). Price is testing the lower Bollinger band at $61.97, which represents the critical support level—a daily close below would confirm a deeper correction toward $58.09. The sharp volume spike (36.8M shares vs. typical 7-13M) is partly mechanical due to the ex-dividend date, suggesting some of today's weakness is not fundamental. The overall verdict is HOLD: existing holders should maintain positions as the long-term trend remains intact, while new buyers should wait for either a reclaim above $64.01 (50 SMA) or a capitulation signal below $61.97 with RSI below 35.
Market Cap
$128.81B
P/E Ratio (TTM)
13.89
Forward P/E
9.61
PEG Ratio
17.71
Price to Book
5.77
EPS (TTM)
$4.54
Forward EPS
$6.56
Dividend Yield
4.01%
Beta
0.227
52-Week High
$68.64
52-Week Low
$42.52
Revenue (TTM)
$49.19B
Gross Profit
$35.25B
EBITDA
$18.93B
Net Income
$9.28B
Profit Margin
18.87%
Operating Margin
34.42%
Return on Equity (ROE)
46.60%
Return on Assets (ROA)
10.72%
Free Cash Flow
$8.11B
Total Assets (Q2 2026)
$87.63B
Goodwill
$21.74B
Other Intangibles
$17.63B
Total Debt
$45.05B
Net Debt
$34.40B
Debt/Equity
201.86%
Stockholders' Equity
$22.32B
Retained Earnings
$20.32B
Treasury Stock
$43.50B
Cash & Equivalents
$8.72B
Net Tangible Assets
($17.05)B
Working Capital
$9.92B
Current Ratio
1.53
R&D Expense (Q2 2026)
$2.96B
Interest Expense (Q2 2026)
$407M
Revenue (Q2 2026)
$12.97B
Diluted EPS (Q2 2026)
$1.62
Net Income (Q2 2026)
$3.32B
Operating Cash Flow (Q2 2026)
$3.39B
Free Cash Flow (Q2 2026)
$3.09B
Strengths
Concerns
BMY presents a value-oriented investment case with a Forward P/E of 9.61 and 4.01% dividend yield, backed by exceptional 46.6% ROE and strong $8.11B TTM free cash flow generation that comfortably covers the ~$5.15B annual dividend. The company is actively deleveraging with total debt reduced by $6B in nine months to $45.05B, while maintaining robust profitability metrics including 34.4% operating margins and 71.7% gross margins. However, significant headwinds include the patent cliff on Eliquis (2026-2027) and Revlimid, elevated leverage with negative tangible book value of ($17.05)B, and pipeline execution requirements for new launches including Cobenfy and Sotyktu to offset generic erosion of legacy franchises.
Macro: Hawkish Fed (95% probability of no cuts in 2026 per Polymarket, $8.4M volume); 10-Year Treasury near 5% with 45% probability of touching 5.2% by year-end; low US recession odds at 8% by end-2026; defensive pharma historically outperforms when 10-year yields elevated without curve steepening into recession.